The Early Decline of alpha-Fetoprotein and Des-gamma-Carboxy Prothrombin Predicts the Response of Hepatic Arterial Infusion Chemotherapy in Hepatocellular Carcinoma Patients by Yamamoto, Shumpei et al.
© 2020 The Author(s)
Published by S. Karger AG, Basel
Research Article
Gastrointest Tumors 2020;7:83–92
The Early Decline of α-Fetoprotein 
and Des-γ-Carboxy Prothrombin 
Predicts the Response of Hepatic 
Arterial Infusion Chemotherapy in 
Hepatocellular Carcinoma Patients
Shumpei Yamamoto    Hideki Onishi    Akinobu Takaki    Atsushi Oyama    
Takuya Adachi    Nozomu Wada    Masahiro Sakata    Tetsuya Yasunaka    
Hidenori Shiraha    Hiroyuki Okada    
Department of Gastroenterology and Hepatology, Okayama University Graduate School of 
Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan
Keywords
Hepatocellular carcinoma · Hepatic arterial infusion chemotherapy · Low-dose cisplatin plus 
5-fluorouracil · α-Fetoprotein · Des-γ-carboxy prothrombin
Abstract
Introduction: Molecular targeting drugs are recommended as second-line treatment for in-
trahepatic advanced hepatocellular carcinoma (HCC). However, in Asia, hepatic arterial infu-
sion chemotherapy (HAIC) is also considered as a second-line treatment because it improves 
the survival of responders. The aim of this study was to predict responders and non-respond-
ers to HAIC with low-dose cisplatin plus 5-fluorouracil (LFP) using tumor markers. Objective 
and Methods: The data of 47 patients who received LFP for the first time in our hospital were 
analyzed retrospectively. We evaluated the association between treatment response by Re-
sponse Evaluation Criteria in Solid Tumors and the changing ratio of the serum concentration 
of α-fetoprotein (AFP), Lens culinaris agglutinin-reactive fraction of AFP (AFP-L3), and des-γ-
carboxy prothrombin (DCP) 2 weeks after LFP initiation. Results: The number of patients 
showing a complete response (CR), a partial response (PR), stable disease (SD), and progres-
sive disease (PD) was 0 (0%), 20 (43%), 18 (38%), and 9 (19%), respectively. The AFP ratio 
showed significant positive correlations for PR vs. SD (p = 0.004) and PR vs. PD (p = 0.003). 
The DCP ratio correlated significantly for PR vs. SD (p = 0.02). The optimal cutoff values for 
responders were 0.79 for the AFP ratio and 0.53 for the DCP ratio. Prediction using both or 
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either cutoff value showed 93% sensitivity, 53% specificity, a 94% negative predictive value, 
and a 57% positive predictive value. Conclusion: Optimal cutoff values for AFP and DCP ratios 
enable prediction of nonresponders to HAIC with LFP. This simple and early assessment meth-
od allows the use of HAIC and molecular targeting drugs for HCC treatment.
© 2020 The Author(s)
Published by S. Karger AG, Basel
Introduction
Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world [1]. 
Although progress and stabilization of treatment for intermediate and advanced HCC improve 
the prognosis of patients, the frequent recurrence of HCC is an unsolvable problem. It has 
often been discussed that repetition of therapies for multiple recurrences results in deterio-
ration of the residual liver function.
In Japanese clinical practice guidelines for HCC [2], hepatic arterial infusion chemo-
therapy (HAIC) and molecular targeting drugs are recommended as second-line treatments 
following transcatheter arterial chemoembolization (TACE) for intrahepatic advanced HCC. 
Although there are no standard criteria that suggest the first choice of treatment for HCC, 
several studies have suggested performing HAIC before the administration of molecular 
targeting drugs because HAIC responders have significantly longer survival rates than HAIC 
nonresponders [3–6]. Therefore, evaluation of the early response in HAIC is important to 
prevent the residual liver function from deteriorating, because molecular targeting drugs are 
indicated for patients with preserved hepatic function (Child-Pugh class A) [7].
The standard methods to assess the efficacy of HAIC are imaging studies such as contrast-
enhanced computed tomography (CECT) and contrast-enhanced magnetic resonance imaging 
(CEMRI) according to Response Evaluation Criteria in Solid Tumors (RECIST) [8], which are 
performed during 1 month after the end of every serial treatment. This means that the 
assessment of treatment response cannot not be confirmed until completion of 1 course, 
which could result in deterioration of the residual liver function. Therefore, some investi-
gators have claimed new ways of early assessment for treatment efficacy using tumor markers, 
such as changing the value of the serum concentration of α-fetoprotein (AFP) and des-gamma-
carboxy prothrombin (DCP) 2 weeks after the initiation of HAIC [4–6]. Although many inves-
tigators have defined the positive response of the AFP and DCP ratio as a reduction of > 20% 
from baseline, little study has been done to actually explore the optimal cutoff value of the 
change ratio of tumor markers in HAIC responders using a statistical method. The aim of the 
present retrospective study is to clarify the optimal cutoff value of the change ratio of tumor 




Between January 2007 and December 2017, one hundred thirty patients with unresectable HCC received 
HAIC treatment at the Department of Gastroenterology and Hepatology, Okayama University Graduate 
School of Medicine, Dentistry and Pharmaceutical Sciences. Of these patients, 53 who received low-dose 
cisplatin (Nihonkayaku, Japan, or Yakult, Japan) plus 5-fluorouracil (5-FU) (Kyowa Hakko, Japan, or Towa, 
Japan) (LFP) for the first time, and were evaluated for AFP, Lens culinaris agglutinin-reactive fraction of AFP 
(AFP-L3), and the DCP level 2 weeks after initiation, were enrolled into this study. We excluded 6 patients 
from this study for the following reasons: (1) presence of extrahepatic metastasis, (2) patients taking 
warfarin, and (3) patients receiving TACE during LFP.
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Chemotherapeutic Regimen
An intra-arterial catheter was inserted through the femoral artery, and an injection port was implanted 
subcutaneously. All of the patients received LFP via the injection port as follows: continuous hepatic arterial 
infusion of 5-FU (250 mg/day, days 1–5) and hepatic arterial infusion of cisplatin (10 mg for 30 min, days 
1–5) daily for every 4 weeks.
Evaluation of the Response to LFP
RECIST guidelines (version 1.1) [8] were used to evaluate the response to LFP through diagnostic 
imaging, such as CECT or CEMRI, which was performed before the initiation of LFP and during 1 month after 
the end of 1 course. We measured the serum concentration of AFP, AFP-L3, and DCP before and 2 weeks after 
the initiation of LFP. Deviation within 2 days before and after the scheduled examination was permitted. The 
AFP ratio was defined as the serum AFP concentration after 2 weeks divided by that observed before the 
initiation of LFP. The AFP-L3 ratio and the DCP ratio were also defined in the same way. We analyzed the 
association of each tumor marker ratio and the diagnostic imaging response of LFP. In each analysis, we 
excluded patients whose tumor marker level was within the normal range before the initiation of LFP.
Statistical Analysis
The JMP version14.0 software package (SAS Institute, Cary, NC, USA) was used for all statistical analyses. 
Continuous variables were expressed as medians (range). Statistical significance was assessed by a nonpara-
metric test. Pearson’s χ2 test or Fisher’s exact test was performed to compare categorical variables. Receiver 
operating characteristic (ROC) curve analysis was used to detect the most appropriate cutoff values for the 
AFP/AFP-L3/DCP ratio to predict the response of LFP. For evaluation of the efficacy of these ratios, sensi-
tivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were calculated.
Results
Patient Characteristics
We enrolled 47 patients who received LFP for the first time to clarify factors that predicted 
responders and nonresponders (Fig. 1). The clinical characteristics of the patients enrolled 
into this study are summarized in Table 1. There were 41 (87%) men, and the median age 
was 65 years. The number of patients with Child-Pugh class A and B was 27 (55%) and 20 
(45%), respectively. The median serum concentration of AFP, AFP-L3, and DCP was 1,538 ng/
130 patients with unresectable HCC who received HAIC
between January 2007 and December 2017
53 patients
47 patients
Received TACE during LFP: 1 patient
Taking warfarin: 1 patient
Extrahepatic metastasis: 4 patients
: 77 patientsii. Not for the first time
iii. Not measured tumor markers after 2 weeks
i. Non-LFP regimen
Fig. 1. Patient enrollment flow chart.
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mL (range 2–554,030), 24.5% (range 0.5–90.9), and 2,469 mAU/mL (range 22–295,980), 
respectively. Moreover, 44 patients (94 %) showed multiple tumors, and the median size of 
the maximum tumor was 45 mm in diameter (range 10–136). Approximately half of the 
patients had locally advanced HCC with vascular invasion at the main trunk or at the first 
branch of the portal vein.
Tumors were larger (p = 0.04) and multiple (p = 0.04) and the serum concentration of 
DCP was significant higher (p = 0.02) in males. There were no significant differences between 
males and females with respect to etiology, Child-Pugh class, portal vein tumor thrombosis, 
or the serum concentration of Hb, PLT, AFP, and AFP-L3.
Association of the AFP/AFP-L3/DCP Ratio with Treatment Response
The number of patients who indicated a complete response (CR), a partial response (PR), 
stable disease (SD), and progressive disease (PD) was 0 (0%), 20 (43%), 18 (38%), and 9 
(19%), respectively. The response rate (RR) was 43%, and the disease control rate was 81%. 
Figure 2 shows the result of the association of the AFP/AFP-L3/DCP ratio with treatment 
response. In the AFP ratio analysis, 6 patients who did not indicate a serum elevation of AFP 
concentration before treatment were excluded. AFP ratio had significantly positive correla-
tions for PR versus SD (p = 0.004) and PR versus PD (p = 0.003). The optimal cutoff value for 
responders (CR+PR) for the AFP ratio was 0.79 and the area under the ROC curve was 0.83.
In the AFP-L3 ratio analysis, 21 patients (43%) who did not show serum elevation of the 
AFP-L3 concentration before the treatment were excluded. AFP-L3 ratio did not show any 
correlation with treatment response.
In the DCP ratio analysis, 2 patients were excluded in the same way. DCP ratio correlated 
significantly for PR versus SD (p = 0.02), while there was no difference for PR versus PD. The 
optimal cutoff value for responder for DCP ratio was 0.53 and the area under the ROC curve 
was 0.69.
Figure 3 shows the result for the association of the pretreatment serum concentration of 
AFP/AFP-L3/DCP with treatment response. None of the serum concentrations did not show 
any correlation with treatment response.
Characteristic Value
Age, years 65 (37–89)
Males 41 (87)
Etiology 
HBs Ag positive/negative 10/37
Anti-HCV positive/negative 26/21
Child-Pugh class A/B/C 27/20/0
Hb, g/dL 12.2 (8.6–17)
PLT, n × 104/μL 12.8 (4–46.4)
AFP, ng/mL 1,538 (2–554,030)
AFP-L3, % 24.5 (0.5–90.9)
DCP, mAU/mL 2,469 (22–295,980)
Maximum tumor size, mm 45 (10–136)
Number of tumors (one/multiple) 3/44
PVTT (main trunk or first branch) 25 (53)
Data are expressed as medians (range) or numbers (%) unless 
otherwise noted. HBsAg, hepatitis B surface antigen; anti-HCV, antibody 
against the hepatitis C virus; Hb, hemoglobin; PLT, platelet; PVTT, 
portal vein tumor thrombosis. 
Table 1. Clinical characteristics of 
47 patients who received LFP for 
the first time
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Fig. 2.  a–c Boxplots representing the changing ratio of AFP, AFP-L3, and DCP, respectively, for patients with 
a PR, SD, and a PD. p values were calculated using a nonparametric test. d–f ROC curve of changing ratios of 
AFP/AFP-L3/DCP for responders (CR+PR).
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Accuracy of the AFP/DCP Ratio in Predicting Responders to LFP
Thirty-nine patients, showing an elevation of both serum AFP and DCP concentrations 
before the treatment, were analyzed to predict responders versus nonresponders using the 
cutoff values of the AFP and DCP ratios (Table 2). Prediction using the AFP ratio was found to 
be 64% sensitive and 88% specific, with an NPV of 81% and a PPV of 75%. With the DCP ratio 
it was found to be 79% sensitive and 64% specific, with an NPV of 84% and a PPV of 55%. 
The prediction using both or either AFP ratios < 0.79 and DCP ratios < 0.53 was 93% sensitive 


































































Fig. 3. a–c Boxplots representing the concentration of AFP, AFP-L3, and DCP, respectively, for patients with 
a PR, SD, and a PD. p values were calculated using a nonparametric test.
Table 2. Accuracy of the AFP/DCP ratio for prediction of the treatment response
Patients Sensitivity Specifity PPV NPV
AFP ratio <0.79 9/14 (64) 22/25 (88) 9/12 (75) 22/27 (81)
DCP ratio <0.53 11/14 (79) 16/25 (64) 11/20 (55) 16/19 (84)
Both or either AFP ratio <0.79 or DCP ratio 
<0.53
13/14 (93) 15/25 (60) 13/23 (57) 15/16 (94)
The total number of patients is 39. Values in parentheses are percents.
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Discussion/Conclusion
Our study indicated that the changing ratio of serum AFP and DCP concentrations 2 
weeks after the initiation of LFP enabled us to predict the response to treatment. 
Furthermore, it can be presumed that, in most patients with intermediate or advanced 
HCC, if the elevation of both serum AFP and DCP concentrations did not satisfy these 2 
cutoff values, then these patients would be considered nonresponders to HAIC with LFP. 
For these patients, we should switch the HAIC treatment with LFP to molecular targeting 
drugs at an early stage.
HAIC has been performed for intrahepatic intermediate or advanced HCC as an effective 
treatment in Asia, especially in Japan. Several studies have been conducted for high RR and 
prolongation of the survival of HCC patients. In several studies, the objective RR of HAIC with 
LFP has been reported to be about 35–71% [9–14, 4–6]. However, it is not recommended as 
standard therapy in the guidelines of American Association for the Study of Liver Disease 
(AASLD) [15] and the European Association for the Study of the Liver (EASL) [16], because 
there are no major randomized clinical trials. However, in a nationwide survey in Japan, a 
propensity score-matched analysis showed that the median survival time was longer for 
patients who received LFP than for patients who did not receive active therapy, and 
responders to LFP showed prolongation of survival [14]. Moreover, Kudo et al. reported the 
efficacy of LFP using a combination of sorafenib and LFP in the SILUS study [17]. Although 
sorafenib plus LFP did not improve the overall survival rate compared to sorafenib mono-
therapy, it showed a tendency to improve the median survival time (MST) in patients with 
main portal invasion (11.4 vs. 6.5 months, p = 0.05). In addition, they pointed out that the 
combination therapy improved the overall RR compared to sorafenib monotherapy, and 
these responders in both treatment groups survived significantly longer than the nonre-
sponders. In this situation, controversy still exists in Japan regarding which treatment should 
be the first choice. Molecular targeting drugs are applied in patients with good liver function 
(i.e., Child-Pugh class A); repeated treatment with HAIC sometimes causes deterioration of 
the liver function [3], and therefore it is important to assess the efficacy of LFP as soon as 
possible.
As some studies have claimed, our study also proved that early evaluation of LFP by the 
changing ratio of tumor markers was effective in predicting the response to treatment. 
Miyaki et al. [4] reported that the combination of early tumor marker response and early 
imaging evaluation at 2 weeks after the initiation of LFP was useful in the assessment of 
treatment response and prognosis. In their study, AFP ratios < 1 and/or DCP ratios < 1 were 
associated with the best imaging response in patients with an SD early imaging response. 
Moreover, Saeki et al. [5, 6] reported that the ACTH system, which consists of the Child Pugh 
score, the AFP response, and the DCP response, is useful for assessment of the treatment 
response and prediction of the survival rate. They defined a positive response as a > 20% 
reduction of AFP and DCP from baseline 2 weeks after the initiation of LFP. However, little 
attention has been paid to the changing ratio of AFP and DCP. It was evident from our findings 
that the optimal cutoff value of AFP and DCP ratios established by ROC analysis could more 
accurately predict responders versus nonresponders for LFP. In fact, DCP tends to decrease 
drastically within 2 weeks after the initiation of LFP compared to AFP in our study. It may 
be associated with the shorter half-life of DCP compared to that of AFP [18, 5]. This result 
implied that the definition about changing ratio of AFP and DCP should be established sepa-
rately. In our study, evaluating the combination of each cutoff value for AFP and DCP ratios 
was quite effective. Only the AFP ratio showed a high sensitivity and NPV to predict the 
treatment response; however, combination of both DCP and AFP ratios achieved a much 
better result.
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The AFP-L3 ratio was not useful in the prediction of treatment response in our study. 
AFP-L3 is a fucosylated variant of AFP, and it changes independently of AFP. AFP-L3 is 
reported to be sensitive and specific for localization of HCC and useful for the early detection 
of HCC [19, 20]. Yamashita et al. [21] reported that AFP-L3-positive patients had a poor prog-
nosis. In their study, the patients tested positive for AFP-L3 earlier than they tested positive 
for AFP during posttreatment observation after percutaneous ethanol injection, TACE, and 
hepatic resection. Okuda et al. [22] showed the efficacy of AFP-L3 to evaluate curability after 
hepatic resection. However, this claim did not concur with our findings. As one of the causes, 
AFP-L3 may not be related to tumor size, although it relates to the presence and malignant 
potential of HCC. For this reason, AFP-L3 may not be suitable for early evaluation of chemo-
therapy, because we cannot expect patients to achieve a CR 2 weeks after the initiation of 
HAIC.
In addition, we analyzed the association of the pretreatment serum concentration of 
AFP/AFP-L3/DCP with treatment response, because the changing ratio of tumor marker was 
likely to be affected by the initial value. As a result, initial serum concentrations were not 
associated with treatment response. This result also suggests that the changing ratio of tumor 
marker is reasonable as a prognostic marker.
It should be mentioned that previous studies included several regimens of HAIC, such as 
LFP with isovorin and 5-FU with subcutaneous interferon [11, 4–6]. The term of 1 course 
depends on the type of regimen, and the reduction rate of tumor markers also depends on 
each regimen. Therefore, we should establish each cutoff value according to the type of 
regimen in the future.
There are 3 limitations to be considered when understanding the results of our study. 
Firstly, this was a retrospective cohort study and data obtained for this study were from a 
single institution. Further prospective multicenter studies with a large sample size are 
needed. Secondly, we excluded the patients who took warfarin and vitamin K, and hence we 
could not test the usefulness of the cutoff values in these patients. Thirdly, we did not analyze 
prognosis, because posttreatments after LFP strongly influence the prognosis.
In conclusion, the combination of optimal cutoff values for the AFP ratio (i.e., 0.79) and 
the DCP ratio (i.e., 0.53) 2 weeks after the initiation of therapy enabled us to predict nonre-
sponders versus responders to HAIC with LFP. Our findings might improve the prognosis as 
they suggest switching to molecular targeting drugs earlier than recommended in previous 
reports.
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